139 related articles for article (PubMed ID: 11886007)
1. Phase II study of weekly docetaxel in patients with metastatic breast cancer.
Aihara T; Kim Y; Takatsuka Y
Ann Oncol; 2002 Feb; 13(2):286-92. PubMed ID: 11886007
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel administered on a weekly basis for metastatic breast cancer.
Burstein HJ; Manola J; Younger J; Parker LM; Bunnell CA; Scheib R; Matulonis UA; Garber JE; Clarke KD; Shulman LN; Winer EP
J Clin Oncol; 2000 Mar; 18(6):1212-9. PubMed ID: 10715290
[TBL] [Abstract][Full Text] [Related]
3. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial.
Hainsworth JD; Burris HA; Yardley DA; Bradof JE; Grimaldi M; Kalman LA; Sullivan T; Baker M; Erland JB; Greco FA
J Clin Oncol; 2001 Aug; 19(15):3500-5. PubMed ID: 11481356
[TBL] [Abstract][Full Text] [Related]
4. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
[TBL] [Abstract][Full Text] [Related]
5. Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment.
Vassilomanolakis M; Koumakis G; Demiri M; Missitzis J; Barbounis V; Efremidis AP
Cancer Invest; 2003; 21(4):497-504. PubMed ID: 14533438
[TBL] [Abstract][Full Text] [Related]
6. Weekly docetaxel in patients with pretreated metastatic breast cancer: a phase II trial.
Mey U; Gorschlüter M; Ziske C; Kleinschmidt R; Glasmacher A; Schmidt-Wolf IG
Anticancer Drugs; 2003 Mar; 14(3):233-8. PubMed ID: 12634618
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
Valero V; Holmes FA; Walters RS; Theriault RL; Esparza L; Fraschini G; Fonseca GA; Bellet RE; Buzdar AU; Hortobagyi GN
J Clin Oncol; 1995 Dec; 13(12):2886-94. PubMed ID: 8523051
[TBL] [Abstract][Full Text] [Related]
8. Weekly docetaxel (Taxotere) in patients with metastatic breast cancer.
Stemmler HJ; Gutschow K; Sommer H; Malekmohammadi M; Kentenich CH; Forstpointner R; Geuenich S; Bischoff J; Hiddemann W; Heinemann V
Ann Oncol; 2001 Oct; 12(10):1393-8. PubMed ID: 11762809
[TBL] [Abstract][Full Text] [Related]
9. A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC.
Fumoleau P; Chevallier B; Kerbrat P; Krakowski Y; Misset JL; Maugard-Louboutin C; Dieras V; Azli N; Bougon N; Riva A; Roche H
Ann Oncol; 1996 Feb; 7(2):165-71. PubMed ID: 8777173
[TBL] [Abstract][Full Text] [Related]
10. Activity and toxicity of docetaxel (Taxotere) in women with previously treated metastatic breast cancer.
Shapiro JD; Millward MJ; Rischin D; Davison JD; Michael M; Francis PA; Ganju V; Toner GC
Aust N Z J Med; 1997 Feb; 27(1):40-4. PubMed ID: 9079252
[TBL] [Abstract][Full Text] [Related]
11. Weekly docetaxel as second-line therapy for patients with advanced breast cancer resistant to previous anthracycline treatment.
Ramos M; González-Ageitos A; Amenedo M; González-Quintas A; Gamazo JL; Togores P; Losada G; Almanza C; Romero C; Gómez-Martín C
J Chemother; 2003 Apr; 15(2):192-7. PubMed ID: 12797398
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of docetaxel and epirubicin in Chinese patients with metastatic breast cancer.
Yeo W; Mok TS; Tse KK; Kwan WH; Lam KC; Ho WM; Chiu SK; Chan AT; Leung TW; Mo FK; Johnson PJ
Anticancer Drugs; 2002 Jul; 13(6):655-62. PubMed ID: 12172512
[TBL] [Abstract][Full Text] [Related]
13. A dose escalation study of weekly docetaxel in patients with advanced solid tumors.
Kouroussis C; Agelaki S; Mavroudis D; Souglakos J; Kakolyris S; Kalbakis K; Vardakis N; Reppa D; Hatzidaki D; Samonis G; Georgoulias V
Cancer Chemother Pharmacol; 2000; 46(6):488-92. PubMed ID: 11138462
[TBL] [Abstract][Full Text] [Related]
14. A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.
Dieras V; Chevallier B; Kerbrat P; Krakowski I; Roche H; Misset JL; Lentz MA; Azli N; Murawsky M; Riva A; Pouillart P; Fumoleau P
Br J Cancer; 1996 Aug; 74(4):650-6. PubMed ID: 8761385
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of docetaxel administered by bi-weekly infusion to patients with metastatic breast cancer.
Shin E; Ishitobi M; Hiraoia M; Kazumasa F; Hideyuki M; Nishisho I; Toshiro S; Yasunori H; Tosimasa T
Anticancer Res; 2000; 20(6C):4721-6. PubMed ID: 11205207
[TBL] [Abstract][Full Text] [Related]
16. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.
Piccart MJ; Klijn J; Paridaens R; Nooij M; Mauriac L; Coleman R; Bontenbal M; Awada A; Selleslags J; Van Vreckem A; Van Glabbeke M
J Clin Oncol; 1997 Sep; 15(9):3149-55. PubMed ID: 9294478
[TBL] [Abstract][Full Text] [Related]
17. Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.
Mackey JR; Tonkin KS; Koski SL; Scarfe AG; Smylie MG; Joy AA; Au HJ; Bodnar DM; Soulieres D; Smith SW
Clin Breast Cancer; 2004 Oct; 5(4):287-92. PubMed ID: 15507175
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
Esteva FJ; Valero V; Booser D; Guerra LT; Murray JL; Pusztai L; Cristofanilli M; Arun B; Esmaeli B; Fritsche HA; Sneige N; Smith TL; Hortobagyi GN
J Clin Oncol; 2002 Apr; 20(7):1800-8. PubMed ID: 11919237
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.
Valero V; Jones SE; Von Hoff DD; Booser DJ; Mennel RG; Ravdin PM; Holmes FA; Rahman Z; Schottstaedt MW; Erban JK; Esparza-Guerra L; Earhart RH; Hortobagyi GN; Burris HA
J Clin Oncol; 1998 Oct; 16(10):3362-8. PubMed ID: 9779713
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.
Chevallier B; Fumoleau P; Kerbrat P; Dieras V; Roche H; Krakowski I; Azli N; Bayssas M; Lentz MA; Van Glabbeke M
J Clin Oncol; 1995 Feb; 13(2):314-22. PubMed ID: 7844592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
